Dataset Information

Analyzing Statistical Mediation with Multiple Informants: A New Approach with an Application in Clinical Psychology.

ABSTRACT: Testing mediation models is critical for identifying potential variables that need to be targeted to effectively change one or more outcome variables. In addition, it is now common practice for clinicians to use multiple informant (MI) data in studies of statistical mediation. By coupling the use of MI data with statistical mediation analysis, clinical researchers can combine the benefits of both techniques. Integrating the information from MIs into a statistical mediation model creates various methodological and practical challenges. The authors review prior methodological approaches to MI mediation analysis in clinical research and propose a new latent variable approach that overcomes some limitations of prior approaches. An application of the new approach to mother, father, and child reports of impulsivity, frustration tolerance, and externalizing problems (N = 454) is presented. The results showed that frustration tolerance mediated the relationship between impulsivity and externalizing problems. The new approach allows for a more comprehensive and effective use of MI data when testing mediation models.

SUBMITTER: Papa LA

PROVIDER: S-EPMC4643137 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Analyzing Statistical Mediation with Multiple Informants: A New Approach with an Application in Clinical Psychology.

Papa Lesther A LA Litson Kaylee K Lockhart Ginger G Chassin Laurie L Geiser Christian C

Frontiers in psychology 20151113

Testing mediation models is critical for identifying potential variables that need to be targeted to effectively change one or more outcome variables. In addition, it is now common practice for clinicians to use multiple informant (MI) data in studies of statistical mediation. By coupling the use of MI data with statistical mediation analysis, clinical researchers can combine the benefits of both techniques. Integrating the information from MIs into a statistical mediation model creates various ...[more]

PMID: 26617536

Similar Datasets

Project description:Recent studies have demonstrated that multiple early-onset diseases have shared risk genes, based on findings from de novo mutations (DNMs). Therefore, we may leverage information from one trait to improve statistical power to identify genes for another trait. However, there are few methods that can jointly analyze DNMs from multiple traits. In this study, we develop a framework called M-DATA (Multi-trait framework for De novo mutation Association Test with Annotations) to increase the statistical power of association analysis by integrating data from multiple correlated traits and their functional annotations. Using the number of DNMs from multiple diseases, we develop a method based on an Expectation-Maximization algorithm to both infer the degree of association between two diseases as well as to estimate the gene association probability for each disease. We apply our method to a case study of jointly analyzing data from congenital heart disease (CHD) and autism. Our method was able to identify 23 genes for CHD from joint analysis, including 12 novel genes, which is substantially more than single-trait analysis, leading to novel insights into CHD disease etiology. Author summary With the development of new generation sequencing technology, germline mutations such as de novo mutations (DNMs) with deleterious effects can be identified to aid in discovering the genetic causes for early on-set diseases such as congenital heart disease (CHD). However, the statistical power is still limited by the small sample size of DNM studies due to the high cost of recruiting and sequencing samples, and the low occurrence of DNMs given its rarity. Compared to DNM analyses for other diseases, it is even more challenging for CHD given its genetic heterogeneity. Recent research has suggested shared disease mechanisms between early-onset neurodevelopmental diseases and CHD based on findings from DNMs. Currently, there are few methods that can jointly analyze DNM data on multiple traits. Therefore, we develop a framework to identify risk genes for multiple traits simultaneously for DNM data. The new method is applied to CHD and autism as a case study to demonstrate its improved power in identifying risk genes compared with single-trait analyses. Our results lead to new insights on the disease etiology of CHD, and the shared etiological mechanisms between CHD and autism.

Project description:PurposeTo develop a statistical approach that compares patient selection strategies across clinical trials and apply this approach to acute ischemic stroke clinical trials to identify the optimal inclusion criteria.MethodsWe developed a statistical approach that compares the number needed to treat to achieve one success (NNT) along with the number needed to screen to achieve one success (NNS) and assesses if there are significant differences in inclusion criteria, treatment course, and clinical outcome among patients that may have been included/excluded in the trials. We applied this approach to the study population from four recent positive acute stroke clinical trials: MR CLEAN, EXTEND-IA, ESCAPE, and SWIFT PRIME, applying published trial criteria to an independent registry of 612 acute stroke patients, since we did not have access to the complete trial data.ResultsAlthough reported NNT were similar for EXTEND-IA, SWIFT PRIME and ESCAPE, and somewhat higher for MR CLEAN, NNS varied across the trials from 21 for EXTEND-IA, 27 for MR CLEAN, to 46 for ESCAPE and 64 for SWIFT PRIME, reflecting less and more stringent inclusion criteria, respectively. Although there were significant differences in imaging biomarkers and other clinical characteristics among patients that may have been included/excluded in the trials, these differences did not translate to significant differences in treatment course or clinical outcomes.ConclusionsOur study proposes a robust statistical approach that can be applied to a larger pooled trial dataset, if made available, to objectively compare across clinical trials and inform inclusion criteria of future trials. Pooled analysis of the acute stroke trial data is needed to determine which imaging biomarker inclusion criteria are critical and which may be relaxed. If this procedure were applied across the pooled trial data, it could decrease costs and refine the design of future trials to be the most efficacious for the greatest number of patients.

Dataset Information

Analyzing Statistical Mediation with Multiple Informants: A New Approach with an Application in Clinical Psychology.

Publications

Analyzing Statistical Mediation with Multiple Informants: A New Approach with an Application in Clinical Psychology.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure